Fox2Now St. Louis

Endovascular Engineering Announces First Patient Enrolled in ENGULF Pivotal Trial with its Hēlo™ PE Thrombectomy System for the Treatment of Pulmonary Embolism

MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous ...
Yahoo Finance

E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference

"On behalf of the ENGULF Investigators, I am proud to share the positive results of the ENGULF study of the Hēlo Thrombectomy System," said Dr. Andrew Klein. "E2 took a unique approach, by innovating ...
KRQE Blogs

Endovascular Engineering's Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism

MENLO PARK, Calif., Jan. 11, 2024 /PRNewswire/ -- Endovascular Engineering ("E2"), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that ...
Yahoo Finance

E2 (Endovascular Engineering, Inc.) Announces Completion of Enrollment in the ENGULF Pivotal Cohort for Treatment of Pulmonary Embolism

Pivotal trial evaluates safety and efficacy of the Hēlo™ PE Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., June 23, 2025 /PRNewswire/ -- E2 (Endovascular ...
East Oregonian

Endovascular Engineering Raises $42 Million in Series B Financing to Advance the Treatment of Pulmonary Embolism

MENLO PARK, Calif., Feb. 18, 2025 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”) has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal ...